TY - JOUR
T1 - Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm
AU - Raut, Pratima
AU - Nimmakayala, Rama Krishna
AU - Batra, Surinder K.
AU - Ponnusamy, Moorthy P.
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2023/1
Y1 - 2023/1
N2 - Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are all considered “Pancreatic cystic neoplasms (PCNs)” and show a varying risk of developing into pancreatic ductal adenocarcinoma (PDAC). These lesions display different molecular characteristics, mutations, and clinical manifestations. A lack of detailed understanding of PCN subtype characteristics and their molecular mechanisms limits the development of efficient diagnostic tools and therapeutic strategies for these lesions. Proper in vivo mouse models that mimic human PCNs are also needed to study the molecular mechanisms and for therapeutic testing. A comprehensive understanding of the current status of PCN biology, mechanisms, current diagnostic methods, and therapies will help in the early detection and proper management of patients with these lesions and PDAC. This review aims to describe all these aspects of PCNs, specifically IPMNs, by describing the future perspectives.
AB - Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are all considered “Pancreatic cystic neoplasms (PCNs)” and show a varying risk of developing into pancreatic ductal adenocarcinoma (PDAC). These lesions display different molecular characteristics, mutations, and clinical manifestations. A lack of detailed understanding of PCN subtype characteristics and their molecular mechanisms limits the development of efficient diagnostic tools and therapeutic strategies for these lesions. Proper in vivo mouse models that mimic human PCNs are also needed to study the molecular mechanisms and for therapeutic testing. A comprehensive understanding of the current status of PCN biology, mechanisms, current diagnostic methods, and therapies will help in the early detection and proper management of patients with these lesions and PDAC. This review aims to describe all these aspects of PCNs, specifically IPMNs, by describing the future perspectives.
KW - Cystic lesions
KW - Cystic neoplasm
KW - Mucinous cystic neoplasm
KW - Pancreatic Intraductal papillary mucinous neoplasm
KW - Pancreatic cancer
KW - Pancreatic ductal adenocarcinoma
KW - Pancreatic precursor lesions
UR - http://www.scopus.com/inward/record.url?scp=85145169468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145169468&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2022.188851
DO - 10.1016/j.bbcan.2022.188851
M3 - Review article
C2 - 36535512
AN - SCOPUS:85145169468
SN - 0304-419X
VL - 1878
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 1
M1 - 188851
ER -